Samsung Bioepis SB27 Proves Equivalence to Keytruda in Cancer Treatment Data
Samsung Bioepis Proves Equivalence of Keytruda Biosimilar SB27
Samsung Bioepis has demonstrated equivalence for its Keytruda biosimilar 'SB27' in global Phase 1 and Phase 3 clinical trials. This is a crucial step toward regulatory approval, part of a strategic move to secure market position ahead of Keytruda's patent expiration.
Keytruda Patent Expiry and Biosimilar Market Competition
Keytruda's global sales amount to approximately 46 trillion won, establishing it as the world's top cancer treatment drug. With Keytruda's patent approaching expiry, Samsung Bioepis has submitted its first biosimilar application ahead of competitors.
Samsung Bioepis confirmed SB27's equivalence through global Phase 1 and Phase 3 trials on June 30, 2026, and filed for domestic product approval on August 10. This strategic move aligns with the expected patent expiry in 2028.
Strategic Moves by Samsung Bioepis
Samsung Bioepis aims to secure a leading position in the K-biotech market through SB27's approval application. CEO Koh Han-sung is driving expansion of related business, anticipating heightened competition in the biosimilar market due to Keytruda's strong sales and impending patent expiry.
Additionally, Samsung Bioepis is focusing on developing next-generation cancer treatments. On April 21, 2026, the company announced non-clinical research on Nectin-4 ADC, signaling efforts to secure future growth drivers.
Position in Global Biosimilar Market
Samsung Bioepis has become a leader in the global biosimilar market. With Keytruda's patent expiry approaching, Samsung Bioepis is targeting the 47 trillion won market, leveraging its proprietary technology to strengthen competitiveness.
Keytruda's global sales of 46 trillion won reaffirm its position as the world's largest cancer treatment drug, and competition between K-biotech companies and global big pharma in this market is expected to intensify. Samsung Bioepis aims to secure an early market lead by being the first to submit SB27 for approval before Keytruda's patent expires.

Clinical Results of Keytruda Biosimilar SB27
Samsung Bioepis confirmed SB27's equivalence in global Phase 1 and Phase 3 clinical trials on June 30, 2026. This means the biosimilar demonstrates identical therapeutic effects to the original drug, serving as a key basis for domestic product approval.
Samsung Bioepis' Strategy for Keytruda Biosimilar Market
Samsung Bioepis submitted SB27 for approval ahead of the 2028 patent expiry, aiming to secure market leadership. Having already established itself as a leader in the global biosimilar market, Samsung Bioepis expects to leverage its proprietary technology to grow in the Keytruda biosimilar segment.
CEO Koh Han-sung is leading efforts to expand related business, reflecting analysis that competition will intensify in the biosimilar market due to Keytruda's high sales and patent expiry.
Status of Next-Generation Cancer Drug Development
Samsung Bioepis is also focusing on developing next-generation cancer treatments beyond its Keytruda biosimilar. On April 21, 2026, the company announced non-clinical research on Nectin-4 ADC, part of efforts to secure new treatment options and strengthen future market competitiveness.
Keytruda Patent Expiry and Market Outlook
Keytruda's patent is set to expire in 2028, leading to intensified competition in the biosimilar market. Samsung Bioepis aims to secure an early lead by being the first to submit SB27 for approval before the patent expires.
With Keytruda's global sales at 46 trillion won, competition between K-biotech companies and global big pharma is expected to intensify in this market. Samsung Bioepis aims to target the 47 trillion won market using its proprietary technology.
Verified Facts vs Unverified Information
It has been confirmed that Samsung Bioepis demonstrated equivalence of Keytruda biosimilar 'SB27' through global clinical trials and filed for domestic approval. However, the company's next-generation Nectin-4 ADC non-clinical research is still in early stages and requires further validation.
Information to Verify
Additional verification is needed regarding Samsung Bioepis' SB27 approval results, including regulatory agency review processes and market launch schedules. The evolving competitive landscape after Keytruda's patent expiry should also be closely monitored.
Frequently Asked Questions
What is Samsung Bioepis' SB27?
SB27 is a biosimilar to Keytruda, designed to deliver identical therapeutic effects as the original drug.
Why is Samsung Bioepis pursuing an early market position in the Keytruda biosimilar market?
To secure market leadership before Keytruda's patent expiry, anticipating intensified competition due to the drug's strong sales and upcoming patent expiration.
What is Samsung Bioepis' status on next-generation cancer drug development?
The company has announced non-clinical research on Nectin-4 ADC and is preparing for further validation toward commercialization.
Frequently Asked Questions
Samsung Bioepis is confirming the therapeutic equivalence of its Keytruda biosimilar 'SB27' through global clinical trials, with domestic approval applications underway. The company is positioning itself to secure market leadership ahead of Keytruda's patent expiry in 2028 while also advancing next-generation cancer treatments.
You can view more articles on similar topics at once.
View Related ArticlesFAQ
What is Samsung Bioepis' SB27?
SB27 is a biosimilar to Keytruda, designed to deliver identical therapeutic effects as the original drug.
Why is Samsung Bioepis pursuing an early market position in the Keytruda biosimilar market?
To secure market leadership before Keytruda's patent expiry, anticipating intensified competition due to the drug's strong sales and upcoming patent expiration.
What is Samsung Bioepis' status on next-generation cancer drug development?
The company has announced non-clinical research on Nectin-4 ADC and is preparing for further validation toward commercialization.
Korean Source
This article is an English localization of a Korean-language report from BlogScore. Original: 삼성바이오에피스 키트루다 효과: 암 치료 성적 데이터